Investigational drug · Phase 3
TEV-53408
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Vitiligo, Celiac Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TEV-53408"
First trial start
2025
Mar 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TEV-53408", any sponsor or status.
Conditions studied
As listed on its trial records.
- Vitiligo
- Celiac Disease
Approved drugs for the same conditions: Immunology and inflammation · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TEV-53408" as an intervention, largest first.
- Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental VitiligoPivotal-lookingNot yet recruiting
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT07920211 · 1,020 participants (planned) · Start Nov 16, 2026 · Primary completion Sep 12, 2030
Drug: TEV-53408 Dose A; TEV-53408 Dose B and 1 more · For: Vitiligo
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT06625177 · 66 participants (planned) · Start Nov 11, 2024 · Primary completion Apr 26, 2028
Drug: TEV-53408 · For: Vitiligo
Sites: Scottsdale, Arizona; Hot Springs, Arkansas; Fremont, California · 13 sites in all
- A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac DiseaseActive, not recruiting
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT06807463 · 50 participants · Start Mar 31, 2025 · Primary completion Oct 2, 2026
Drug: TEV-53408; Placebo · For: Celiac Disease
Sites: Murrieta, California; Colorado Springs, Colorado; Inverness, Florida · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Modeling human natural killer cell development and drug response in a microfluidic bone marrow model.
Koenig L, Ben-Eliezer I, Tao TP, et al. · Front Immunol 2025
Also in development for Vitiligo
- MH004Phase 32 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Vitiligo, Atopic Dermatitis (AD)
- GR2301Phase 22 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Vitiligo
- LY4005130Phase 22 trials
Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)
- SHR0302BasePhase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Vitiligo, Non-segmental Vitiligo
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Teva.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.